Oculis Holding AG announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 11, 2025. For the full year 2024, the company reported a net loss of CHF 95.310 million, which narrowed by approximately 9.8% compared to a net loss of CHF 105.720 million in 2023. Research and Development (R&D) expenses for the full year 2024 were CHF 57.87 million, consistent with the full year 2023, while General and Administrative (G&A) expenses increased to CHF 23.68 million from CHF 20.08 million in 2023.
For the fourth quarter of 2024, the net loss was CHF 38.188 million, compared to CHF 29.417 million in Q4 2023. The company highlighted its recent $100 million equity financing as a significant milestone, providing capital to propel its pipeline. As of January 6, 2025, Oculis reported approximately $105 to $110 million in cash, cash equivalents, and short-term investments.
Operationally, Oculis delivered positive Phase 2 topline readouts for Privosegtor (OCS-05) in acute optic neuritis and Licaminlimab (OCS-02) in dry eye disease. The company also confirmed it is on track to complete enrollment for both Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema in the coming months. An R&D Day is scheduled for April 15, 2025, to provide further updates on portfolio strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.